Enveric Biosciences, a biotechnology company, has announced encouraging preclinical results showing EB-003 has no photoreactive potential in in vitro testing—a key safety milestone that further reduces development risk for the candidate.

 

The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors, with the goal of delivering rapid, long-lasting antidepressant and anxiolytic effects in a convenient outpatient setting.

 

Phototoxicity assessment, required under FDA-aligned ICH S10 guidelines, evaluates whether compounds could trigger harmful reactions when exposed to ultraviolet light. Photoactive drugs can sometimes cause severe sunburn-like responses, skin irritation, or blistering in sun-exposed areas, potentially limiting their therapeutic use.

 

“The demonstration of limited potential for phototoxicity enhances the favorable safety profile of EB-003,” said Joseph Tucker, CEO of Enveric Biosciences. “We continue to de-risk EB-003 as we look forward to initiating first-in-human Phase 1 clinical trials and remain committed to meeting the highest standards of safety as we progress towards the clinic.”